Scientific and technological achievements of Hangzhou Huadong Pharmaceutical Group Co., Ltd.

The group company is good at seizing the opportunity, and by virtue of the advantages and development potential of high-tech pharmaceutical products, it has become one of the "Top Ten Enterprise Groups in Hangzhou" and the 18 Large Enterprise Group specially cultivated by the Zhejiang Provincial Government, and also one of the 520 "National Key Enterprises" of the State Economic and Trade Commission. Development and industrialization of secopin

Mortimer's mycophenolate mofetil and its tablets obtained the first production approval in China, successfully evaded the administrative protection of imported preparations, seized market opportunities, and complemented cyclosporine in the field of immunosuppressant formation, winning the China Prize for Excellence in Invention Patent. 20 1 1 annual sales revenue1.500 million yuan. Development and industrialization of pantoprazole

Pantoprazole sodium, its capsules and injections obtained the first batch of domestic production approvals, which filled the blank of the company's injections (freeze-drying) and patented its prescription. 20 1 1 year, the product sales income exceeds 270 million yuan. Development and industrialization of bailing capsule

Fermented Cordyceps powder, the earliest national traditional Chinese medicine in Zhejiang Province. The annual sales revenue of 201/kloc-0 exceeded 560 million yuan, making it the largest single product in Zhejiang province. Development and industrialization of carboine

China's first imitation acarbose and its tablets were protected for six years, which pioneered the company's diabetes medication field, filled the gap of China's long-term dependence on imported drugs in the field of diabetes treatment, and won the first prize of scientific and technological progress of the Ministry of Education. 20 1 1 annual sales revenue exceeded 350 million yuan. Development and industrialization of Geely powder

Known as "the first needle in China", recombinant human granulocyte stimulating factor injection filled the gap in China and occupied the second place in the domestic market, winning the second prize of national key new products and the Zhejiang Science and Technology Progress Award. The annual product sales of 20 1/kloc-0 is nearly1100 million yuan, accounting for 55% of the total annual sales of Jiuyuan Gene. Development and industrialization of Cespin

Cyclosporine and its preparation, the first in China and the second in the world, obtained the production number, which broke the monopoly of large foreign companies, became a landmark product in the field of organ transplantation in China and won the second prize of national scientific and technological progress. The sales revenue of 20 1 1 exceeds 2.4.